Zydus launches IBYRA, the generic version of Olaparib
The drug will target specific genetic mutations prevalent in certain types of cancers
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
PARP inhibitor
J&J’s Akeega FDA approval to heat up PARP battle with dual-action treatment for prostate…
Akeega’s current predicted sales will experience only a slight increase as a result of its narrow label and fierce competition…
BDR Pharma launches generic Rucaparib to treat advanced ovarian and prostate cancers
Rucaparib is launched under the brand name BDPARIB in two strengths of 200 mg and 300 mg